The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee

Elisabeth Strandhagen*1, Henrik Zetterberg2,3, Nibia Aires1, Mona Palmér2, Lars Rymo2, Kaj Blennow2,3 and Dag S Thelle1

Abstract

Background: The response of serum cholesterol to diet may be affected by the apolipoprotein E (APOE) ε2/ε3/ε4 polymorphism, which also is a significant predictor of variation in the risk of coronary heart disease (CHD) and CHD death. Here, we test the hypothesis that the APOE polymorphism may modulate the cholesterol-raising effect of coffee.

Objective: We determined the effect of a coffee abstention period and a daily intake of 600 mL of coffee on serum cholesterol and triglycerides with respect to the APOE polymorphism.

Design: 121 healthy, non-smoking men (22%) and women (78%) aged 29–65 years, took part in a study with four intervention periods: 1) and 3) a coffee-free period of three weeks, 2) and 4) 600 mL coffee/day for four weeks.

Results: APOE ε2 positive individuals had significantly lower total cholesterol concentration at baseline (4.68 mmol/L and 5.28 mmol/L, respectively, p = 0.01), but the cholesterol-raising effect of coffee was not influenced significantly by APOE allele carrier status.

Conclusions: The APOE ε2 allele is associated with lower serum cholesterol concentration. However, the APOE polymorphism does not seem to influence the cholesterol-raising effect of coffee.

Introduction

Apolipoprotein E (apoE) is a structural component of triglyceride-rich lipoproteins, chylomicrons, very-low-density lipoproteins (VLDL), and high-density-lipoproteins (HDL) [1]. Variation in the APOE gene sequence results in the 3 common alleles (ε2, ε3 and ε4), which can produce 6 different genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4). The ε2, ε3 and ε4 alleles encode three distinct forms of apoE (E2, E3 and E4) and have approximate frequencies of 8%, 77%, and 15%, respectively, in white
populations [2]. ApoE3 seems to be the normal isoform in all known functions, while apoE4 and apoE2 can each be dysfunctional [3,4]. In most populations, individuals with the APOE ε2 allele display lower levels of plasma cholesterol compared with individuals carrying the APOE ε3 allele, whereas individuals with the APOE ε4 allele show higher levels of plasma cholesterol, especially LDL-cholesterol [1,2,5]. Subjects with APOE ε3/ε4 and ε4/ε4 genotypes absorb cholesterol effectively and have higher non-fasting serum triglyceride values than ε4 negative individuals [6,7]. The allelic variation in the APOE gene is shown to be a significant predictor of variation in the risk of coronary heart disease (CHD) and CHD death [2-4,8-10], but the results from an extensive prospective study showed no associations [11]. Both the MONICA Project [12] and the Scandinavian Simvastatin Survival Study [13] suggest an increased risk of CHD for individuals carrying the APOE ε4 allele. The APOE ε4 allele is also considered a strong risk factor for Alzheimer's disease [14-16].

The serum cholesterol-raising effect of coffee is due to the diterpenes kahweol and cafestol [17]. Earlier studies have shown a cholesterol-raising effect mainly of unfiltered coffee, because a major part of the diterpenes is retained by a paper filter [18-20]. A recent trial, however, indicates that filtered coffee has a more pronounced serum cholesterol-raising effect than previously anticipated [21]. This finding was further corroborated in a randomized intervention study, where we demonstrated a considerable cholesterol-raising effect of filtered coffee [22]. In the study two coffee abstinence periods were associated with a significant decline in serum cholesterol of 0.22 and 0.36 mmol/L, respectively, while 600 mL filtered coffee a day during two different periods increased serum cholesterol by 0.25 and 0.15 mmol/L, respectively. Here, we test the hypothesis that these effects might be modulated by the APOE ε2/ε3/ε4 polymorphism.

**Subjects and methods**

**Trial design**

The study was organised as a prospective, controlled study with four consecutive trial periods. The first and third periods were 3 weeks of total coffee abstention. The second and fourth period consisted of 4 weeks with the subjects consuming 600 mL filter brewed coffee/day.

The main outcome or effect variable was total serum cholesterol and the effect was assessed as the difference between the measurements at the beginning and the end of the coffee free periods (coffee abstention) and the difference between measurements at the beginning and at the end of the four weeks of coffee consumption (Figure 1). Trial duration of 3–4 weeks has previously been shown to be sufficient to get an effect of coffee on serum cholesterol [21,23].

**Subjects and procedure**

Participants were recruited by advertising in Gothenburg's major newspaper. Inclusion criteria were age-range 30–65 years, free from clinically recognized chronic diseases, such as cardiovascular diseases, cancer, renal disorders, liver disease and diabetes mellitus. The participants were required to be free from anti-epileptic or cholesterol lowering drugs, and had been using coffee on a regular basis for at least five years and were currently non-smokers (at least for the last six months).

| 3 weeks of coffee abstention | 4 weeks of coffee consumption (600mL/day) | 3 weeks of coffee abstention | 4 weeks of coffee consumption (600mL/day) |
|-----------------------------|----------------------------------------|-----------------------------|----------------------------------------|
| w0                          | w1                                     | w2                          | w3                                     |
| w4                          | w5                                     | w6                          | w7                                     |
| w8                          | w9                                     | w10                         | w11                                    |
| w12                         | w13                                    | w14                         |                                        |

1. `w = week`
2. `BS = Blood samples: serum cholesterol, serum HDL cholesterol, serum triglycerides, serum Lp(a)`

**Figure 1**

Study design
During the coffee drinking periods the participants were instructed to drink about 600 mL filter brewed coffee/day (4 cups), according to standardised measures. The coffee was provided to guarantee that they were all exposed to the same brand and quality of filter brewed coffee. All participants also got the same kind of standardised coffee filter and measuring spoon.

The coffee filters used were of the brand Euro-Shopper, made by Indupa N.V., Zaventem, Belgium. Divergence from the 4 cups was reported. The participants were allowed to drink tea and other caffeine containing beverages during the coffee-free periods.

**Effect variables**
Non-fasting blood samples were drawn at inclusion and at three, seven, ten and fourteen weeks after start of the study. Prior to analysis, prepared serum was stored at -70°C.

The blood samples were analysed for blood lipids (total cholesterol, HDL cholesterol, triglycerides, lipoprotein(a) (Lp(a)) and urate in serum. Serum cholesterol and triglycerides were determined by an enzymatic procedure on a Hitachi 917 analyzer. HDL cholesterol was determined enzymatically after precipitation of VLDL, LDL and chylomicrons by α-cyclodextrin sulphate and dextran sulphate. Determination of Lp(a) was done by the method Tint Elize Lp(a) of Biopool International. Serum urate was analysed by Hitachi 917 autoanalyser. Body Mass Index (BMI; kg/m²) was recorded once during the study. Blood pressure was recorded by manual device and EKG and heart rate were recorded at all five visits.

The dietary habits were assessed by dietary frequency questionnaires at the beginning of the study. A follow-up survey with special emphasis on changes in food habits during the four different periods was undertaken. The dietary questionnaire was based upon a Norwegian version, which has been used in a number of previous studies [24].

**Genotype Analysis**
APOE genotypes were determined by solid-phase minisequencing as previously described by Blennow et al [25].

**Statistical methods**
All analyses were performed using the SAS®software version 8. Signed rank test was used to test differences in the groups. Wilcoxon rank sum test was used to test differences at baseline and differences between the groups. The mean was used as location measure and measures of variation were described in terms of standard deviation. P-values < 0.05 were considered statistically significant.

**Table 1: APOE genotype and allele frequency, n = 121**

|          | n | %  |
|----------|---|----|
| ε2/ε2    | 2 | 1.7 |
| ε2/ε3    | 9 | 7.4 |
| ε2/ε4    | 2 | 1.7 |
| ε3/ε3    | 69| 57.0|
| ε3/ε4    | 36| 29.8|
| ε4/ε4    | 3 | 2.5 |
| ε2      | 15| 6.2 |
| ε3      | 183| 75.6|
| ε4      | 44| 18.2|

**Table 2: Serum cholesterol concentration (mmol/L) at baseline and after two 3-week periods of coffee abstention (week 0 – 3 and week 7 – 10) for APOE ε2-positive (n = 13) and APOE ε2-negative (n = 108) individuals**

|                      | APOE ε2-positive | APOE ε2-negative | p     |
|----------------------|------------------|------------------|-------|
|                      | n = 13           | n = 107/103 a    |       |
| First trial period   |                  |                  |       |
| week 0               | 4.68 (0.80)      | 5.28 (0.93)      | 0.01b |
| week 3               | 4.49 (0.71)      | 5.05 (0.90)      |       |
| diff week 0–3        | -0.18 (0.24)     | -0.23 (0.55)     | 0.30c |
| p (diff 0–3)         | 0.02 d           | <0.0001d         |       |
| Second trial period  |                  |                  |       |
| week 7               | 4.52 (0.71)      | 5.34 (0.93)      |       |
| week 10              | 4.34 (0.64)      | 4.95 (0.89)      |       |
| week 7–10            | -0.18 (0.41)     | -0.39 (0.55)     | 0.08  |
| p (diff 7–10)        | 0.13             | <0.0001d         |       |

a 107 participants in the first trial period and 103 participants in the second trial period
b Significant difference between APOE ε2-positive and APOE ε2-negative at baseline, Wilcoxon rank sum test
c No significant difference between APOE ε2-positive and APOE ε2-negative in differences between week 0–3 or week 7–10, Wilcoxon rank sum test
d Significant difference between week 0–3 for the APOE ε2-positive group and between week 0–3 and week 7–10 for the APOE ε2-negative group, Signed rank test

**Results**
A total of 156 persons responded to the advertisement and of these 124 fulfilled the criteria and were able to take part. Three persons decided to withdraw during the study, leaving a total of 121 participants. One person was not able to take part during the first two periods and five persons were not able to take part in the last two periods, which resulted in 120 participants in the first trial period and 116 in the subsequent trial period.
serum cholesterol, serum HDL cholesterol, serum triglycerides or serum Lp(a), possibly due to a small sample size (data not shown). ε4-positive individuals had similar serum cholesterol levels and coffee-induced changes in cholesterol concentration as ε4-negative individuals (data not shown). However, when grouping ε2-positive individuals it was revealed that these displayed significantly lower cholesterol at baseline (Table 2). There was a significant difference in cholesterol decrease between week 0 and 3 for both groups. There was no difference between the two groups regarding the cholesterol decrease in the first coffee abstention period but there was a significant difference in cholesterol decrease in the second coffee abstention period, where ε2-negative individuals displayed a larger decrease in cholesterol (Table 2).

Coffee consumption resulted in a significant cholesterol increase in the ε2-negative group in both trial periods (w 3–7 and w 10–14), but not in the ε2-positive group (Table 3). There were no differences between the ε2-positive and the ε2-negative group according to baseline characteristics as sex, age, body mass index (BMI) and coffee consumption prior to the study (Table 4).

**Dietary monitoring and compliance**

The dietary survey did not reveal any important changes during the four intervention periods [22]. Coffee consumption or non-compliance was reported by six persons during the first coffee abstention period (mean 1.8 cups/period), whereas four persons reported coffee consumption in the second coffee abstention period (mean 0.7 cups/period).

**Discussion**

Subjects with different APOE genotypes differ in the absorption efficiency of cholesterol from the intestine, in the synthesis rates of cholesterol and bile acids, and in the production of LDL apoprotein B [3,26]. This suggests that the response of serum cholesterol to diet may be affected by the APOE €2/€3/€4 polymorphism [27,28]. One previous study examined the effect of purified cafestol on serum lipids in relation to the APOE polymorphism [26] and found that responses of LDL-cholesterol to cafestol were slightly smaller among carriers of the APOE ε4 allele. Here, we investigate for the first time the possible influence of the APOE polymorphism on the cholesterol-raising effect of filtered coffee.

APOE ε4-positive individuals did not differ significantly from ε4-negative individuals with regard to baseline cholesterol concentration or coffee-induced changes in cholesterol concentration. However, we confirm that ε2-positive individuals display significantly lower cholesterol levels at baseline than ε2-negative individuals. A tendency was seen that ε2-positive individuals might be partly pro-

---

**Table 3: Serum cholesterol concentration (mmol/L) after two 4-week periods of coffee consumption (week 3 – 7 and week 10 – 14) for APOE ε2-positive (n = 13) and APOE ε2-negative (n = 108) individuals**

|                   | APOE ε2-positive | APOE ε2-negative | p     |
|-------------------|-----------------|-----------------|-------|
| **First trial period** |                 |                 |       |
| week 3            | 4.49 (0.71)     | 5.05 (0.90)     |       |
| week 7            | 4.52 (0.71)     | 5.34 (0.93)     |       |
| diff week 3–7     | 0.03 (0.57)     | 0.29 (0.57)     | 0.0   |
| p (diff 3–7)      | 0.70            | <0.0001         |       |
| **Second trial period** |               |                 |       |
| week 10           | 4.34 (0.64)     | 4.95 (0.89)     |       |
| week 14           | 4.54 (0.84)     | 5.09 (0.85)     |       |
| diff week 10–14   | 0.20 (0.47)     | 0.14 (0.59)     | 0.3   |
| p (diff 10–14)    | 0.15            | 0.009           |       |

*107 participants in the first trial period and 103 participants in the second trial period.

*No significant difference between 2-positive and 2-negative in differences between week 3–7 or week 10–14, Wilcoxon rank sum test.

*Significant difference between week 0–3 and week 7–10 for the APOE ε2-negative group, Signed rank test.

**Table 4: Baseline characteristics for APOE ε2-positive (n = 13) and APOE ε2-negative (n = 108) individuals**

|                   | APOE ε2-positive | APOE ε2-negative | p     |
|-------------------|-----------------|-----------------|-------|
| Sex (% women)     | 77              | 79              | ns    |
| Age (years)       | 46.6            | 48.7            | 0.44  |
| BMI (kg/m²)       | 25.7            | 25.8            | 0.87  |
| Coffee consumption (cups/day) | 4.3      | 3.7             | 0.12  |

*No significant difference between APOE ε2-positive and APOE ε2-negative at baseline, Chi square test.

*No significant difference between APOE ε2-positive and APOE ε2-negative at baseline, Wilcoxon rank sum test.

**Genotype frequencies**

The APOE allele frequencies were 6.1% for the ε2 allele, 75.6% for the ε3 allele and 18.2% for the ε4 allele. This distribution agrees well with those reported in other populations in northern Europe [2,3]. Genotype and allele frequencies for the APOE polymorphism are given in Table 1.

**Serum cholesterol concentrations according to genotype and coffee exposure**

Individual APOE genotypes (six subgroups, Table 1) did not influence baseline values or coffee-induced changes in
ected from the cholesterol increasing effect of coffee consumption. This was, however, only seen in the first trial period and will require further investigations. In conclusion, the APOE ε2/ε3/ε4 polymorphism is not a strong modulator of the cholesterol-increasing effect of coffee. Other genes should be discussed and further investigation is needed to see if there is a genetic factor in the cholesterol-raising effect of coffee.

Acknowledgements
This work was supported by grants from the Swedish Medical Research Council (project #12103), the Sahlgrenska University Hospital and the Swedish Council for Working Life and Social Research.

References
1. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiyama H, Fujiwara H, Kawata K, Saito M, Kikuchi S, Noguchi Y, Sugishita Y, Hamaguchi H: Methionine content of coffee. Brofolic acid reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998, 137:23-28.
2. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 1988, 81:21.
3. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC: Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002, 155:487-491.
4. Mahley RW, Rall SC: APOLIPOPROTEIN E: Far More Than a Lipid Transport Protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
5. Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004, 141:137-147.
6. Tammi A, Rönnemaa T, Rask-Nissilä L, Miettinen TA, Gylling H, Valsta L, Viikari J, Valimäki I, Simell O: Apolipoprotein E Phenotype Regulates Cholesterol Absorption in Healthy 13-Month-Old Children-The STRIP Study. Pediatr Res 2001, 50:688-691.
7. Tammi A, Rönnemaa T, Viikari J, Jokinen E, Lapinleimu H, Ehnholm C, Simell O: Apolipoprotein E4 phenotype increases non-fasting serum triglyceride concentration in infants – the STRIP study. Atherosclerosis 2000, 152:35-141.
8. Stengård JH, Peukkanen J, Ehnholm C, Nissinen A, Sing CF: Genotypes with the apolipoprotein -4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Hum Genet 1996, 97:677-684.
9. Ilveskoski E, Perola M, Lehtimäki T, Laitinen L, Savolainen V, Pajarijan J, Penttilä A, Lalu KH, Mannikko A, Liisto KK, Koivula T, Karhunen PJ: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men. An autopsy study. Circulation 1999, 100:608-613.
10. Corbo RM, Scacchi R, Vilardo T, Ruggeri M: Polymorphisms in the Apolipoprotein E gene regulatory region in relation to coronary heart disease and their effect on plasma Apolipoprotein E. Clin Chem Lab Med 2001, 39:2-6.
11. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ: A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2003, 166:323-9.
12. Stengård JH, Weiss KM, Sing CF: An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet 1998, 101:234-41.
13. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, Kesanen YTA, Fagerman O: The apolipoprotein E ε allele determines prognosis and the effect on prognosis of simvas- tatin in survivors of myocardial infarction. A subs study of the Scandinavian Simvastatin Survival Study. Circulation 2000, 101:1366-71.
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261:921-923.
15. Poirier J, Davignon J, Bouchard C, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993, 342:697-699.
16. Strittmatter WJ, Saunders AM, Schmechel DE, Pericak-Vance MA, Eng- hild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease. Proc Natl Acad Sci USA 1993, 90:1977-1981.
17. Urgert R, Katan B: The cholesterol-raising factor from coffee beans. Annu Rev Nutr 1997, 17:305-324.
18. Dick A: Coffee and cardiovascular risk; an epidemiological study. In PhD thesis Erasmus University Rotterdam; 1990.
19. Ahola I, Jauhiainen M, Aro A: The hypercholesterolaemic factor of boiled coffee is retained by a paper filter. J Inter Med 1991, 230:293-297.
20. Van Dusseldorp M, Katan MB, Van Vliet T, Demacker PNM, Stalen hoef A: Cholesterol-raising factor from boiled coffee does not pass a paper filter. Arterioscler Thromb 1991, 11:586-593.
21. Christensen B, Mosdøl A, Retterstøl L, Landaa S, Thelle DS: Abstention from filtered coffee reduces the levels of homocysteine and cholesterol – a randomized, controlled trial. Ann J Clin Nutr 2001, 74:302-307.
22. Strandhagen E, Thelle DS: Filtered coffee raises serum cholester ol: results from a controlled study. Eur J Clin Nutr 2003, 57:1164-1168.
23. Grubb I, Boers GH, Blom HJ, Broekhuizen R, de Jong R, van Rijt L, de Ruiter E, Swinkels DW, Nagengast FM, Katan MB: Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial. Ann J Clin Nutr 2000, 71:480-484.
24. Neet M, Frost Andersen L, Solvoll K, Sandstad B, Hustvedt BE, Leve A, Drevon C: Accuracy of a quantitative food frequency questionnaire applied in elderly Norwegian women. Eur J Clin Nutr 1992, 46:809-21.
25. Blannow K, Kirckton A, Prince JA, Brookes AJ, Emaeziano T, Wassila vik C, Bogdanovic N, Andreasen N, Batman S, Marcussjon J, Nagga K, Wallin A, Regland B, Olfofsen H, Hesse C, Daviddsson P, Minthon L, Jansson A, Palmqvist L, Rymo L: No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2001, 107:1065-79.
26. Weggemans RM, Zock PL, Orordova JM, Pedro-Botet J, Katan MB: Apoprotein E genotype and the response of serum cholesterol to dietary intervention. Atherosclerosis 2001, 154:517-555.
27. Masson LF, McNeill G, Avenell A: Genetic variation and the lipid response to dietary intervention: a systematic review. Ann J Clin Nutr 2003, 77:1098-1111.
28. Orordova MJ: Gene-diet interaction and plasma lipid responses to dietary intervention. Biochem Soc Trans 2002, 30:68-73.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

BioMed Central